Generic Name and Formulations:
Metyrosine 250mg; caps.
Valeant Pharmaceuticals, Inc
Treatment of pheochromocytoma for: preoperative preparation for surgery; or management when surgery is contraindicated. Chronic treatment in malignant pheochromocytoma.
Initially 250mg 4 times daily; may increase by 250–500mg daily up to max 4g/day in divided doses. Usual dose: 2–3g/day; monitor. If hypertensive, titrate dose to normalize BP and control symptoms; if normotensive, titrate dose to reduce urinary metanephrines and/or vanillylmandelic acid by ≥50%. Add an α-blocker (eg, phenoxybenzamine) if patients not adequately controlled. Pre-op prep: treat for at least 5–7 days.
Renal or hepatic impairment. Maintain adequate hydration; if crystalluria occurs, increase more fluids; if crystalluria persists, reduce dose or discontinue. Pre-op use: maintain adequate intravascular volume intra- and postoperatively. Pregnancy (Cat.C). Nursing mothers.
Increased CNS effects with alcohol, other CNS depressants (eg, hypnotics, sedatives, tranquilizers). Potentiates extrapyramidal effects of phenothiazines, haloperidol.
Tyrosine hydroxylase inhibitor.
Sedation, diarrhea, extrapyramidal effects, anxiety, CNS disturbances, crystalluria; rare: hematological disorders.
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...